Clinical outcomes associated with anti ‐Xa‐monitored enoxaparin for venous thromboembolism prophylaxis

ConclusionsThirty-day clinical outcomes in patients receiving enoxaparin for VTE prophylaxis were not improved by anti-Xa monitoring. Our results support current evidence-based guideline recommendations against anti-Xa monitoring for patients receiving enoxaparin for VTE prophylaxis.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 26, 2023 Category: Drugs & Pharmacology Authors: John A. Saunders, Sara R. Vazquez, Joseph A. Hill, Daniel M. Witt Tags: RESEARCH ARTICLE Source Type: research